Literature DB >> 35579257

RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression.

Yanni Huang1,2, Yizi Zheng1,3, Ling Yao1,2, Feng Qiao4, Yifeng Hou1,2, Xin Hu1,2,4, Daqiang Li1,2,5, Zhiming Shao1,2,4.   

Abstract

RNA binding proteins (RBPs) play pivotal roles in breast cancer (BC) development. As an RBP, Processing of precursor 7 (POP7) is one of the subunits of RNase P and RNase MRP, however, its exact function and mechanism in BC remain unknown. Here, we showed that expression of POP7 was frequently increased in BC cells and in primary breast tumors. Upregulated POP7 significantly promoted BC cell proliferation in vitro and primary tumor growth in vivo. POP7 also increased cell migration, invasion in vitro, and lung metastasis in vivo. Through RNA immunoprecipitation coupled with sequencing (RIP-seq), we found that POP7 bound preferentially to intron regions and POP7-binding peak associated genes were mainly enriched in cancer-related pathways. Furthermore, POP7 regulated Interleukin Enhancer Binding Factor 3 (ILF3) expression through influencing its mRNA stability. Knockdown of ILF3 significantly impaired the increased malignant potential of POP7-overexpressing cells, suggesting that POP7 enhances BC progression through regulating ILF3 expression. Collectively, our findings provide the first evidence for the important role of POP7 and its regulation of ILF3 in promoting BC progression.
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  ILF3; POP7; RNA binding protein; breast cancer; mRNA stability

Year:  2022        PMID: 35579257     DOI: 10.1111/cas.15430

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.518


  1 in total

1.  Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of Prunella vulgaris L. in Treating Breast Cancer.

Authors:  Haotian Bai; Rui Wang; Yalan Li; Xiao Liang; Junhao Zhang; Na Sun; Jing Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-10       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.